CALLIDITAS THERAPEUTICS AB

Analyst Reco. Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Real-time Estimate Cboe Europe Other stock markets 02:37:33 06/05/2024 pm IST			5-day change	1st Jan Change
108.6 ^SEK	+1.83%		+1.78%	-14.40%

10:58am	Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints	MT
08:00am	Calliditas Therapeutics AB Announces Positive Topline Results of Phase 2 Head and Neck Cancer Trial with Lead NOX Inhibitor Candidate, Setanaxib	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Adjusts Calliditas Therapeutics' Price Target to $18 From $21, Keeps Neutral Rating	18/23/18	MT
HC Wainwright Initiates Coverage on Calliditas Therapeutics With Buy Rating, $60 Price Target	20/23/20	MT
Guggenheim Initiates Calliditas Therapeutics at Neutral With $18 Price Target	01/23/01	MT
HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates Buy Rating	20/21/20	MT
Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy Rating	20/21/20	MT
ANALYST RECOMMENDATIONS : Alibaba, Goldman Sachs, Monday.com, Shaftesbury, 3M Company...	07/21/07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW